Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis

J. M. Ponseti; J. Azem; J. M. Fort; M. López-Cano; R. Vilallonga; M. Buera; C. Cervera; M. Armengol

doi:https://doi.org/10.1212/01.WNL.0000160392.32894.6D

Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis

J. M. Ponseti, J. Azem, J. M. Fort, M. López-Cano, R. Vilallonga, M. Buera, C. Cervera, M. Armengol

Department of Surgery

Research output: Contribution to journal › Article › Research › peer-review

65 Citations (Scopus)

Abstract

Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 ± 0.8 years. Prednisone was withdrawn in all but two patients. Anti-acetylcholine antibodies and MG score for disease severity decreased significantly and muscular strength increased by 39%. Complete stable remission was achieved in 5% of patients and pharmacologic remission in 87.3%. All patients resumed full activities of daily living. Copyright © 2005 by AAN Enterprises, Inc.

Original language	English
Pages (from-to)	1641-1643
Journal	Neurology
Volume	64
DOIs	https://doi.org/10.1212/01.WNL.0000160392.32894.6D
Publication status	Published - 10 May 2005

Access to Document

https://doi.org/10.1212/01.WNL.0000160392.32894.6D

Fingerprint Dive into the research topics of 'Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis'. Together they form a unique fingerprint.

Cite this

@article{1598671a2db34a4893bf7b92f676b0a1,

title = "Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis",

abstract = "Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 ± 0.8 years. Prednisone was withdrawn in all but two patients. Anti-acetylcholine antibodies and MG score for disease severity decreased significantly and muscular strength increased by 39%. Complete stable remission was achieved in 5% of patients and pharmacologic remission in 87.3%. All patients resumed full activities of daily living. Copyright {\textcopyright} 2005 by AAN Enterprises, Inc.",

author = "Ponseti, {J. M.} and J. Azem and Fort, {J. M.} and M. L{\'o}pez-Cano and R. Vilallonga and M. Buera and C. Cervera and M. Armengol",

year = "2005",

month = may,

day = "10",

doi = "https://doi.org/10.1212/01.WNL.0000160392.32894.6D",

language = "English",

volume = "64",

pages = "1641--1643",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis

AU - Ponseti, J. M.

AU - Azem, J.

AU - Fort, J. M.

AU - López-Cano, M.

AU - Vilallonga, R.

AU - Buera, M.

AU - Cervera, C.

AU - Armengol, M.

PY - 2005/5/10

Y1 - 2005/5/10

N2 - Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 ± 0.8 years. Prednisone was withdrawn in all but two patients. Anti-acetylcholine antibodies and MG score for disease severity decreased significantly and muscular strength increased by 39%. Complete stable remission was achieved in 5% of patients and pharmacologic remission in 87.3%. All patients resumed full activities of daily living. Copyright © 2005 by AAN Enterprises, Inc.

AB - Seventy-nine patients with cyclosporine- and prednisone-dependent myasthenia gravis (MG) after thymectomy received tacrolimus for a mean of 2.5 ± 0.8 years. Prednisone was withdrawn in all but two patients. Anti-acetylcholine antibodies and MG score for disease severity decreased significantly and muscular strength increased by 39%. Complete stable remission was achieved in 5% of patients and pharmacologic remission in 87.3%. All patients resumed full activities of daily living. Copyright © 2005 by AAN Enterprises, Inc.

U2 - https://doi.org/10.1212/01.WNL.0000160392.32894.6D

DO - https://doi.org/10.1212/01.WNL.0000160392.32894.6D

M3 - Article

VL - 64

SP - 1641

EP - 1643

JO - Neurology

JF - Neurology

SN - 0028-3878

ER -